In today’s recent session, 0.88 million shares of the Iovance Biotherapeutics Inc (NASDAQ:IOVA) have been traded, and its beta is 0.60. Most recently the company’s share price was $10.16, and it changed around -$0.3 or -2.87% from the last close, which brings the market valuation of the company to $3.08B. IOVA at last check was trading at a discount to its 52-week high of $18.33, offering almost -80.41% off that amount. The share price’s 52-week low was $3.21, which indicates that the recent value has risen by an impressive 68.41% since then. We note from Iovance Biotherapeutics Inc’s average daily trading volume that its 10-day average is 3.98 million shares, with the 3-month average coming to 6.33 million.
Iovance Biotherapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended IOVA as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Iovance Biotherapeutics Inc is expected to report earnings per share of -0.3 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Instantly IOVA has been showing red trend so far today with a performance of -2.87% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 10.47 on recent trading dayincreased the stock’s daily price by 2.96%. The company’s shares are currently up 24.97% year-to-date, but still up 8.20% over the last five days. On the other hand, Iovance Biotherapeutics Inc (NASDAQ:IOVA) is 1.50% up in the 30-day period. We can see from the shorts that 60.29 million shares have been sold at a short interest cover period of 9.56 day(s).
The consensus price target as assigned by Wall Street analysts is $23, which translates to bulls needing to increase their stock price by 55.83% from its current value. Analyst projections state that IOVA is forecast to be at a low of $6 and a high of $40.
Iovance Biotherapeutics Inc (IOVA) estimates and forecasts
Iovance Biotherapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -22.26 percent over the past six months and at a 32.80% annual growth rate that is well above the industry average of 17.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 34.80% in revenue this quarter, and will report an increase of 40.00% in the next quarter. The year-over-year growth rate is expected to be 13,563.60%, up from the previous year.
Consensus estimates provided by 12 financial analysts predict the company will bring in an average of 53.79M in revenue for the current quarter. 12 analysts expect Iovance Biotherapeutics Inc to make 77.18M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 469k and 482k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 11,369.10%. Forecasts for the next quarter put sales growth at 15,912.40%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -8.25%.
IOVA Dividends
Iovance Biotherapeutics Inc’s next quarterly earnings report is expected to be released on 2024-Oct-30.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.53% of Iovance Biotherapeutics Inc shares, and 87.27% of them are in the hands of institutional investors. The stock currently has a share float of 87.74%. Iovance Biotherapeutics Inc stock is held by 389.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 9.7478% of the shares, which is about 25.95 million shares worth $208.12 million.
PERCEPTIVE ADVISORS LLC, with 9.7412% or 25.93 million shares worth $207.98 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF were the top two Mutual Funds as of Jun 30, 2024. The former held 7.89 shares worth $79.72 million, making up 2.82% of all outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held roughly 7.33 shares worth around $74.09 million, which represents about 2.62% of the total shares outstanding.
